ALTERITY THERAPEUTICS LTD

Alterity Therapeutics announced it has received an A$3.98 million research and development (R&D) tax refund for the 2025 financial year. This refund, which includes A$43,117 in interest, is provided under the Australian Government's R&D tax incentive program. The company plans to use these funds to support the ongoing development of its clinical programs, particularly its lead asset ATH434 for neurodegenerative diseases.

Alterity Therapeutics announced it received official FDA minutes confirming the outcomes of its End-of-Phase 2 meeting for ATH434 in Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial, supported by confirmatory evidence from the Phase 2 trial, could support approval. The company remains on track to initiate Phase 3 trial activities by year-end 2026, with the study expected to enroll approximately 200 patients.

Alterity Therapeutics announced it received official FDA End-of-Phase 2 meeting minutes, confirming the registrational pathway for ATH434 in Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial, supported by confirmatory evidence from the Phase 2 trial, could be sufficient for approval. The company is on track to initiate Phase 3 trial activities by year-end 2026, with the study expected to enroll approximately 200 patients.

Alterity Therapeutics Limited filed a Form 6-K with the SEC to report the submission of an application for the quotation of its securities, identified as ATH. This filing indicates a procedural step related to the company's listed securities.

Alterity Therapeutics Limited filed a Form 6-K on June 17, 2026, reporting changes in director's interests. The filing, signed by Chairman Julian Babarczy, incorporates by reference into several registration statements.

Alterity Therapeutics Limited filed a Form 6-K report for the month of June 2026. The filing includes a corporate presentation from June 2026 as an exhibit. The company indicated it files annual reports under Form 20-F. The filing was signed by Julian Babarczy, Chairman, on June 16, 2026.

Alterity Therapeutics Limited filed a Form 6-K report for the month of June 2026. This report is being incorporated by reference into existing Registration Statements on Form S-8 and Form F-3. The filing includes Exhibit 99.1, which is a Notification of cessation of securities for ATH.

Alterity Therapeutics Limited has filed a Form 6-K report for June 2026. This report is being incorporated by reference into existing Registration Statements on Form S-8 and Form F-3. The filing includes Exhibit 99.1, which is a notification regarding unquoted securities.

Alterity Therapeutics announced a successful End-of-Phase 2 meeting with the U.S. FDA for ATH434 in Multiple System Atrophy (MSA). The FDA agreed on key elements of the proposed Phase 3 design, including the study population, dosing regimen (50mg twice daily), treatment duration, and UMSARS Part I as the primary endpoint. This agreement de-risks the registrational program, with Phase 3 trial activities expected to commence by year-end 2026.

Alterity Therapeutics announced successful alignment with the U.S. FDA on the key elements of its registrational Phase 3 program for ATH434 in Multiple System Atrophy (MSA). The FDA agreed on the proposed trial design, including the study population, treatment duration, and the 11-item UMSARS Part I rating scale as the primary endpoint. The 50 mg twice daily dose, which demonstrated 48% slowing of disease progression in Phase 2, was also concurred upon. This agreement de-risks the development pathway, with pivotal Phase 3 trial activities expected to commence by year-end 2026.